TABLE 1.
Participant characteristics
| No cardiotoxic treatment (n = 88) | Cardiotoxic chemotherapy (n = 32) | Cardiotoxic radiation (n = 63) | Cardiotoxic chemotherapy and radiation (n = 17) | p‐value | |
|---|---|---|---|---|---|
| Age at diagnosis (years) |
Median = 50.0 (IQR = 12.0) |
Median = 48.5 (IQR = 9.5) |
Median = 52.0 (IQR = 11.0) |
Median = 50.0 (IQR = 10.0) |
0.10 |
| Age at imaging (years) |
Median = 62.0 (IQR = 13.3) |
Median = 60.7 (IQR = 8.5) |
Median = 63.9 (IQR = 10.3) |
Median = 59.9 (IQR = 9.8) |
0.15 |
| Time interval from diagnosis (years) |
Median = 11.0 (IQR = 2.4) |
Median = 12.2 (IQR = 1.8) |
Median = 11.5 (IQR = 2.1) |
Median = 11.9 (IQR = 2.0) |
0.06 |
| Hypertension | 28/88 (31.8%) | 5/32 (15.6%) | 15/63 (23.8%) | 5/17 (29.4%) | 0.32 |
| Smoking history | 29/88 (33.0%) | 7/32 (21.9%) | 19/63 (30.2%) | 6/17 (35.3%) | 0.67 |
| Obesity | 20/87 (23.0%) | 7/32 (21.9%) | 17/61 (27.9%) | 8/17 (47.1%) | 0.22 |
| Disease recurrence | 17/88 (19.3%) | 4/32 (12.5%) | 18/63 (28.6%) | 3/17 (17.6%) | 0.30 |
| Chronic kidney disease | 1/88 (1.1%) | 0/32 (0.0%) | 0/63 (0.0%) | 0/17 (0.0%) | 1.00 |
| Targeted therapy | 6/88 (6.8%) | 5/32 (15.6%) | 5/63 (7.9%) | 1/17 (5.9%) | 0.49 |
| Hormonal therapy | 18/88 (20.4%) | 12/32 (37.5%) | 17/63 (27.0%) | 10/17 (58.4%) | 0.01 |
| Dyslipidemia | 28/59 (32.2%) | 14/32 (43.8%) | 22/61 (36.0%) | 8/16 (50.0%) | 0.43 |
| Atrial fibrillation | 3/88 (3.4%) | 0/32 (0.0%) | 1/63 (1.6%) | 1/17 (5.9%) | 0.47 |
| TIA | 3/88 (3.4%) | 0/32 (0.0%) | 0/63 (0.0%) | 0/17 (0.0%) | 0.46 |
| Left sided breast cancer | 17/87 (19.5%) | 12/32 (37.5%) | 63/63 (100.0%) | 17/17 (100.0%) | <0.001 |
| Diabetes mellitus | 8/86 (9.3%) | 4/32 (12.5%) | 16/60 (26.7%) | 2/17 (11.8%) | 0.04 |
| Family history of premature cardiac disease | 52/87 (59.8%) | 20/31 (64.5%) | 39/61 (63.9%) | 12/17 (70.6%) | 0.86 |
| Ethnicity (African American/Black) | 5/88 (5.7%) | 4/32 (12.5%) | 6/63 (9.5%) | 2/17 (11.8%) | 0.57 |
| Ethnicity (White/Caucasian) | 75/88 (85.2%) | 24/32 (75.0%) | 52/63 (82.5%) | 12/17 (70.6%) | |
| Ethnicity (all other) | 8/88 (9.1%) | 4/32 (12.5%) | 5/63 (7.9%) | 3/17 (17.7%) |
The Kruskal‐Wallis test was used to compare age and time interval by treatment group. Medians and IQRs were used for age and time interval, as these variables were not normally distributed. Fisher's exact test was used to compare categorical risk factors by treatment group. A p‐value of <0.05 was considered statistically significant.